CD19 and systemic sclerosis: While it warrants further study for confirmation, this report suggests pathogenicity of Scl70 autoantibodies in SSc and is the first to describe the recovery of FcγR-expressing NK cells by CD19.CAR-T cell-containing immunosuppressive therapy in autoimmune PPF.